Summit Trail Advisors’s Briacell Therapeutics BCTX Stock Holding History

Summit Trail Advisors’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-233	Closed	-$43.4K	–	440
2024 Q3	$43.4K	Hold	233	–	–	﹤0.01%	713
2024 Q2	$39.9K	Hold	233	–	–	﹤0.01%	611
2024 Q1	$100K	Hold	233	–	–	﹤0.01%	584
2023 Q4	$205K	Hold	233	–	–	0.01%	497
2023 Q3	$219K	Hold	233	–	–	0.01%	481
2023 Q2	$225K	Hold	233	–	–	0.01%	449
2023 Q1	$261K	Hold	233	–	–	0.01%	345
2022 Q4	$153K	Hold	233	–	–	0.01%	373
2022 Q3	$197K	Hold	233	–	–	0.01%	337
2022 Q2	$202K	Hold	233	–	–	0.01%	352
2022 Q1	$355K	Hold	233	–	–	0.03%	216
2021 Q4	$290K	Hold	233	–	–	0.02%	235
2021 Q3	$284K	Hold	233	–	–	0.02%	205
2021 Q2	$187K	Buy	+233	New	+$145K	0.02%	209

Other funds holding BCTX

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

OBWG

Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Summit Trail Advisors's BCTX Position: Q4 2024 in Review

Summit Trail Advisors sold out of Briacell Therapeutics (BCTX) in Q4 2024, closing a stake of 233 shares — an estimated $43.4K sold.

Summit Trail Advisors first reported a position in BCTX in Q2 2021 and held it in 14 quarters. The position peaked at $355K in Q1 2022. 25 funds tracked by Wall St. Rank hold BCTX as of Q4 2024.

Summit Trail Advisors reported no remaining Briacell Therapeutics position as of Q4 2024 after selling out during the quarter.
Summit Trail Advisors sold 233 Briacell Therapeutics shares in Q4 2024, an estimated $43.4K.
Summit Trail Advisors first reported a position in Briacell Therapeutics in Q2 2021 and held it in 14 quarters.
Summit Trail Advisors's Briacell Therapeutics position peaked at $355K in Q1 2022.
25 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2024.

Based on Summit Trail Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.